ArticleTrials2025

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Alexis Ogdie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.